VASOPRESSIN INJECTION, USP SOLUTION

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

VASOPRESSIN

Доступно од:

FRESENIUS KABI CANADA LTD

АТЦ код:

H01BA01

INN (Међународно име):

VASOPRESSIN (ARGIPRESSIN)

Дозирање:

20UNIT

Фармацеутски облик:

SOLUTION

Састав:

VASOPRESSIN 20UNIT

Пут администрације:

INTRAMUSCULAR

Јединице у пакету:

1ML

Тип рецептора:

Prescription

Терапеутска област:

PITUITARY

Резиме производа:

Active ingredient group (AIG) number: 0106469001; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

1998-07-02

Карактеристике производа

Prescribing Information - Vasopressin Injection, USP
Page 1 of 9_ _
PRESCRIBING INFORMATION
PR
VASOPRESSIN INJECTION, USP
Vasopressin Injection
Sterile Solution
20 USP units / mL
Synthetic
For Intramuscular (IM) or Subcutaneous (SC) Injection
Antidiuretic Agent
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Initial Authorization:
OCT 03, 1994
Date of Revision:
MAR 28, 2022
Submission Control Number: 255357
Prescribing Information - Vasopressin Injection, USP
Page 2 of 9_ _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
03/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
03/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..................................................................................................2
TABLE OF CONTENTS
..................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS......................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
....................................................................4
4
DOSAGE AND ADMINISTRATION
.......................................................................................5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
...............................................